Background
Methods
Patient selection
FOLFOX Treatment
Data collection and assessment of adjuvant chemotherapy prognosis
Statistical analysis
Results
Characteristics of the study population
Variables | Number of cases | Percentage(%) |
---|---|---|
Follow-up(months)
| ||
Median(range) | 31(7–103) | |
Age(years)
| ||
Median(range) | 59(22–82) | |
Pretreatment albumin
| ||
≥35 g/L | 173 | 71.2 |
<35 g/L | 70 | 28.8 |
Pretreatment CEA
a
| ||
≤10 ng/ml | 186 | 76.5 |
>10 ng/ml | 57 | 23.5 |
Differentiation
| ||
High | 24 | 9.9 |
Middle | 198 | 81.5 |
Low | 21 | 8.6 |
Sex
| ||
Male | 134 | 55.1 |
Female | 109 | 44.9 |
Age
| ||
≤49 years | 56 | 23.0 |
50-60 yeas | 72 | 29.6 |
>60 years | 115 | 47.3 |
am
| ||
Rectum | 111 | 45.7 |
Left colon cancer | 77 | 31.7 |
Right colon cancer | 55 | 22.6 |
Stage
| ||
II | 140 | 57.6 |
III | 103 | 42.4 |
Baseline neutrophil counts(×10
9
/L)
| ||
Mean(± SD) | 4.27 ± 1.49 | |
Baseline lymphocyte counts(×10
9
/L)
| ||
Mean(± SD) | 1.88 ± 0.59 | |
Chemotherapy-associated neutrophil counts
| ||
Neutrophil counts ≥ 1.5 × 109/L | 153 | 63.0 |
Neutropenia < 1.5 × 109/L | 90 | 37.0 |
Chemotherapy-associated lymphocyte counts
| ||
Lymphocyte counts ≥ 1.0 × 109/L | 139 | 57.2 |
Lymphopenia < 1.0 × 109/L | 104 | 42.8 |
The prognostic value of chemotherapy-associated neutrophil/ lymphocyte counts on CRC recurrence/death
The prognostic value of chemotherapy-associated lymphopenia <0.66 × 109/L, 0.91 × 109/L for colorectal cancer
Variables | Hazard ratio | 95% confidence intervals | P-value |
---|---|---|---|
Pretreatment albumin
| |||
≥35 g/L | 1.00(ref.) | ||
<35 g/L | 1.000 | 0. 592–1. 692 | 0.999 |
Pretreatment CEA
a
| |||
<10 ng ml-1
| 1.00(ref.) | ||
≥10 ng ml-1
| 1. 827 | 1.040-3.211 | 0.036 |
Differentiation
| |||
Well | 1.00(ref.) | ||
Moderately | 0. 676 | 0. 292–1.567 | 0.361 |
Low | 0.882 | 0.294-2.644 | 0.823 |
Sex
| |||
Male | 1.00(ref.) | ||
Female | 1.018 | 0.616-1.682 | 0.946 |
Age
| |||
≤49 years | 1.00(ref.) | ||
50-60 yeas | 1.612 | 0.750-3.465 | 0.222 |
>60 years | 1.386 | 0.673-2.854 | 0.376 |
Location
| |||
Rectum | 1.00(ref.) | ||
Left colon cancer | 0.873 | 0.483-1.576 | 0.651 |
Right colon cancer | 0.850 | 0.438-1.649 | 0.630 |
Stage
| |||
II | 1.00(ref.) | ||
III | 2.723 | 1.549-4.786 | 0.001 |
Duration of lymphopenia <1.0 × 10
9
L
| |||
≤28 days | 1.00(ref.) | ||
> 28 days | 0.556 | 0.243-1.273 | 0.165 |
Chemotherapy-associated lymphocyte counts
| |||
Lymphocyte counts ≥ 0.66 × 109/L | 1.00(ref.) | ||
Lymphopenia <0.66 × 109/L | 3.521 | 1.703-7.282 | 0.001 |
Variables | Hazard ratio | 95% confidence intervals | P-value |
---|---|---|---|
Pretreatment albumin
| |||
≥35 g/L | 1.00(ref.) | ||
<35 g/L | 1.140 | 0.648-2.007 | 0.649 |
Pretreatment CEA
a
| |||
<10 ng ml-1
| 1.00(ref.) | ||
≥10 ng ml-1
| 1. 900 | 1.056-3.416 | 0.032 |
Differentiation
| |||
Well | 1.00(ref.) | ||
Moderately | 0. 865 | 0. 323–2.314 | 0.772 |
Low | 1.097 | 0.311-3.871 | 0.885 |
Sex
| |||
Male | 1.00(ref.) | ||
Female | 0.856 | 0.493-1.489 | 0.583 |
Age
| |||
≤49 years | 1.00(ref.) | ||
50-60 yeas | 1.514 | 0.625-3.666 | 0.359 |
>60 years | 1.587 | 0.698-3.607 | 0.271 |
Location
| |||
Rectum | 1.00(ref.) | ||
Left colon cancer | 1.067 | 0.564-2.019 | 0.843 |
Right colon cancer | 0.647 | 0.296-1.414 | 0.275 |
Stage
| |||
II | 1.00(ref.) | ||
III | 3.641 | 1.980-6.697 | <0.0001 |
Duration of lymphopenia <1.0 × 10
9
L
| |||
≤28 days | 1.00(ref.) | ||
> 28 days | 0.770 | 0.341-1.740 | 0.530 |
Chemotherapy-associated lymphocyte counts
| |||
Lymphocyte counts ≥ 0.66 × 109/L | 1.00(ref.) | ||
Lymphopenia <0.66 × 109/L | 2.083 | 1.103-3.936 | 0.024 |
The risk factors for chemotherapy-associated lymphopenia <0.66×109/L /0.91 × 109/L in colorectal cancer
Variables | Odds ratio | 95% confidence intervals | P-value |
---|---|---|---|
Pretreatment albumin
| |||
≥35 g/L | 1.00(ref.) | ||
<35 g/L | 0.685 | 0.302-1.550 | 0.363 |
Pretreatment CEA
a
| |||
<10 ng ml-1
| 1.00(ref.) | ||
≥10 ng ml-1
| 3.338 | 1.523-7.315 | 0.003 |
Differentiation
| |||
Well | 1.00(ref.) | ||
Moderately | 1.200 | 0.308-4.678 | 0.793 |
Low | 3.049 | 0.553-16.828 | 0.201 |
Sex
| |||
Male | 1.00(ref.) | ||
Female | 1.219 | 0.600-2.474 | 0.584 |
Age
| |||
≤49 years | 1.00(ref.) | ||
50-60 yeas | 0.840 | 0.271-2.608 | 0.763 |
>60 years | 2.358 | 0.904-6.154 | 0.080 |
Location
| |||
Rectum | 1.00(ref.) | ||
Left colon cancer | 1.056 | 0.484-2.300 | 0.892 |
Right colon cancer | 0.532 | 0.192-1.475 | 0.225 |
Stage
| |||
II | 1.00(ref.) | ||
III | 0.847 | 0.403-1.781 | 0.661 |
Variables | Odds ratio | 95% confidence intervals | P-value |
---|---|---|---|
Pretreatment albumin
| |||
≥35 g/L | 1.00(ref.) | ||
<35 g/L | 1.410 | 0.772-2.576 | 0.263 |
Pretreatment CEA
a
| |||
<10 ng ml-1
| 1.00(ref.) | ||
≥10 ng ml-1
| 1.885 | 0.984-3.610 | 0.056 |
Differentiation
| |||
Well | 1.00(ref.) | ||
Moderately | 1.590 | 0.564-4.483 | 0.381 |
Low | 2.694 | 0.694-10.458 | 0.152 |
Sex
| |||
Male | 1.00(ref.) | ||
Female | 1.725 | 0.987-3.016 | 0.056 |
Age
| |||
≤49 years | 1.00(ref.) | ||
50-60 yeas | 1.617 | 0.705-3.709 | 0.256 |
>60 years | 2.872 | 1.344-6.136 | 0.006 |
Location
| |||
Rectum | 1.00(ref.) | ||
Left colon cancer | 0.948 | 0.502-1.789 | 0.869 |
Right colon cancer | 0.780 | 0.381-1.596 | 0.496 |
Stage
| |||
II | 1.00(ref.) | ||
III | 0.881 | 0.494-1.572 | 0.668 |